Congresses

Title Yearsort ascending
The veterinary anthelmintic selamectin inhibits the mycobacterial DprE1 enzyme 2022
Repurposing Beta-lactams for Buruli Ulcer Therapy, from the Bench to the Clinic 2022
Recapitulation of pulmonary SARS-CoV-2 infection in vitro in a novel 3D human lung organoid model with innate immune and stromal cells 2022
Shortening Buruli ulcer treatment: the BLMs4BU clinical trial 2022
Shortening Buruli Ulcer treatment: the BLMS4BU clinical trial 2022
Study of in vitro and in vivo activity of a novel compound against Mycobacterium abscessus for the treatment of cystic fibrosis infections 2022
A drug candidate against Mycobacterium abscessus and other cystic fibrosis pathogens 2022
Régimen con betalactámicos para reducir el tratamiento de la úlcera de Buruli: tratamiento estándar de 8 semanas (rifampicina más claritromicina) versus 4 semanas de tratamiento estándar más amoxicilina/clavulanato [RC8 vs. RCA4] (ensayo clínico BLMs4BU) 2022
Multicentric in-vitro characterization of MPL-204, a new anti- tuberculosis drug candidate, by the ERA4TB collaborative initiative 2022
OPTIKA, a new high content in vitro kill-kinetic assay to evaluate the efficacy of novel anti-TB drug combinations 2022
In vitro synergy screens of FDA-approved drugs combined with last-line antibiotics reveal new bactericidal combinations against Klebsiella pneumoniae 2022
Hollow fiber system for tuberculosis setting up at university of Zaragoza 2022
Shortening Buruli ulcer treatment: the BLMs4BU clinical trial 2022
In vitro killing dynamics of the diarylquinolone TBAJ-587 and its main metabolites against Mycobacterium tuberculosis 2022
Shortening Buruli ulcer treatment: WHO recommended <i>vs.</i> a novel betalactam containing therapy - Phase II and Phase III studies in West Africa (the BLMs4BU clinical trial) 2022
OPTIKA, A New High Content Drug Combination Kill Kinetic Assay 2022
Hollow fiber system for TB: optimization studies with Moxifloxacin 2022
OPTIKA – a new high content drug combination dynamic assay / Hollow-fibre models 2022
A new weapon against Mycobacterium abscessus 2022
In vitro time-kill assays of amoxicillin/clavulanate in combination with rifampicin/clarithromycin against Mycobacterium ulcerans 2022

Pages